Cargando…
The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?
High sustained virologic response (SVR) rates have been observed after 6 weeks of anti-HCV treatment using sofosbuvir, ledipasvir and a non-nucleoside polymerase-inhibitor (GS-9669) or a protease-inhibitor (GS-9451) and after 12 weeks with sofosbuvir + ledipasvir. Here we analyze the viral kinetics...
Autores principales: | Nguyen, Thi Huyen Tram, Guedj, Jérémie, Uprichard, Susan L., Kohli, Anita, Kottilil, Shyam, Perelson, Alan S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579268/ https://www.ncbi.nlm.nih.gov/pubmed/28860456 http://dx.doi.org/10.1038/s41598-017-09776-z |
Ejemplares similares
-
Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies
por: Malespin, Miguel, et al.
Publicado: (2016) -
Zika virus dynamics: Effects of inoculum dose, the innate immune response and viral interference
por: Best, Katharine, et al.
Publicado: (2021) -
Safe and effective sofosbuvir-based therapy in patients with mental health disease on hepatitis C virus treatment
por: Tang, Lydia Shuk Yee, et al.
Publicado: (2016) -
Standard ganciclovir dosing results in slow decline of cytomegalovirus viral loads
por: Märtson, Anne-Grete, et al.
Publicado: (2021) -
Tickling the TLR7 to cure viral hepatitis
por: Funk, Emily, et al.
Publicado: (2014)